Physician profile
Nirmala Tumarada
NPI 1184060923
$3,321.39
in general payments reported to CMS, 2019-2025
32 companies · $695 in 2025
The $695 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.72 · 2020: $939 · 2021: $102 · 2022: $1,070 · 2023: $68.62 · 2024: $430 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,193.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $857.82 | 2020 | |
| Neurocrine Biosciences, INC. | $368.54 | 2024-2025 | Ingrezza |
| Abbvie INC. | $331.14 | 2021-2025 | Ubrelvy, Qulipta |
| Argenx US, INC. | $171.41 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Biohaven Pharmaceutical Holding Company Ltd. | $159.68 | 2022 | |
| Genzyme Corporation | $149.11 | 2022 | |
| Emd Serono, INC. | $137.56 | 2020-2022 | |
| Eisai INC. | $130.97 | 2025 | |
| Pfizer INC. | $122.24 | 2023-2025 | |
| Sk Life Science, INC. | $98.45 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $91.52 | 2021-2022 | |
| Lundbeck LLC | $89.84 | 2024-2025 | Vyepti |
| Alnylam Pharmaceuticals INC. | $76.18 | 2022 | |
| Biogen, INC. | $71.23 | 2022-2025 | Skyclarys, Leqembi |
| Novartis Pharmaceuticals Corporation | $44.55 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $42.97 | 2020-2022 | |
| Acadia Pharmaceuticals INC | $41.84 | 2024-2025 | Nuplazid |
| Biohaven Pharmaceuticals, INC. | $40.93 | 2021 | |
| Lilly USA, LLC | $37.86 | 2022-2025 | Kisunla |
| Horizon Therapeutics Plc | $34.01 | 2022 | |
| Allergan, INC. | $27.00 | 2020 | |
| Life Molecular Imaging Ltd | $25.94 | 2025 | Neuraceq |
| Collegium Pharmaceutical, INC. | $23.53 | 2022 | |
| Ucb, INC. | $21.75 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.25 | 2024 | Dojolvi |
| Grifols USA, LLC | $18.68 | 2025 | Gamunex-C |
| Cycle Pharmaceuticals INC | $17.31 | 2025 | Tascenso Odt, Bafiertam |
| Celgene Corporation | $16.71 | 2022 | |
| Strongbridge US INC. | $16.48 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $14.79 | 2025 | Rexulti |
| Medtronic, INC. | $14.70 | 2022 | |
| Insightec,INC | $7.40 | 2024 | Exablate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirmala Tumarada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.